A new study suggests that administering nirsevimab, an RSV antibody, to infants not only prevents severe respiratory illness but also leads to fewer antibiotic prescriptions, potentially helping combat antibiotic overuse in young children.
A new study from the Children’s Hospital of Philadelphia suggests that infants who receive nirsevimab, the RSV antibody, are prescribed fewer antibiotics for respiratory infections in the months after treatment. Published in Clinical Infectious Diseases, the analysis reviewed electronic health records for 15,341 babies under eight months old across 32 practices in the CHOP Primary Care Network and found lower antibiotic use among those who received the shot.
The main benefit of nirsevimab remains the same: preventing serious RSV illness in babies. But the study points to a secondary advantage that may matter to parents and clinicians alike. Because RSV can look like a bacterial infection and can also set off ear infections or pneumonia, it often leads to antibiotic prescribing even when antibiotics are not needed. In outpatient RSV cases, antibiotics are commonly used despite the virus being the underlying cause.
Researchers found that, compared with no treatment, nirsevimab was linked with a 14.4% reduction in antibiotic prescribing for outpatient acute respiratory infections, a 40.3% drop for outpatient bronchiolitis and a 69.4% reduction in antibiotics associated with RSV-related hospitalisations. The hospital-related estimate was less precise than the outpatient findings, with a wide confidence interval, which means the true effect could be smaller than the headline number suggests. The study authors said the results support nirsevimab as a tool for antibiotic stewardship.
The findings fit with broader CDC guidance that recommends a single dose of nirsevimab for infants younger than eight months entering their first RSV season. The agency’s review and evidence framework were built around preventing RSV lower respiratory tract infection, not reducing antibiotic use, but the new data suggest that fewer RSV infections may also mean fewer visits where antibiotics are prescribed. Earlier CDC surveillance studies have already shown that nirsevimab lowers RSV hospitalisations and severe outcomes such as intensive care admissions and acute respiratory failure.
For parents, the practical message is unchanged. Nirsevimab is not a reason to skip an antibiotic when a doctor believes one is needed, but it may help avoid some prescriptions that would otherwise follow a viral illness. Researchers also note that the study was observational and limited to one large health system, so it cannot prove cause and effect or stand in for nationwide data. Even so, it adds another layer to the case for protecting young infants before RSV season begins.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
